Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns

Explore established industry leaders with impressive dividend yields that are demonstrating the potential for growth and continued performance in 2025.

MarketBeat

Teen's Breast Grew To Triple G-Cup Size After COVID Vaccinations: Researchers Call It 'Exceedingly Rare'

Researchers have identified the condition as Pseudoangiomatous stromal hyperplasia (PASH)-associated gigantomastia, an "exceedingly rare" condition linked to COVID-19 vaccination.

Medical Daily

Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Top 3 Stocks Seeing a Spike in Call Option Volume

Three stocks reported unusual call option volume this month, and the reasons why would make sense to all investors and Wall Street analysts.

MarketBeat

Pfizer: 4 Reasons to Buy This Stock

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca

MarketBeat

Judge in Luigi Mangione Case Married to Ex-Pfizer Executive, Owns Thousands in Healthcare Stock: Report

The judge presiding over pre-trial hearings for Luigi Mangione has come under scrutiny for her financial and familial ties to the healthcare industry.

Latin Times

Love Dividends? 2 Passive Income Stocks to Scoop Up Now.

These consistent dividend-paying stocks could be a good addition to your portfolio.

Barchart

Read news from The Economist, FT, and more,
with one subscription

‘Heartless’ multinationals exploiting pensions loophole for UK workers

Hewlett Packard, American Express and Pfizer among firms to have frozen increases in payouts despite inflation

The Guardian - UK

Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.

Investors Business Daily

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and Robert F. Kennedy Jr. as the possible HHS lead.

Investors Business Daily

Stock Index Futures Gain With All Eyes on Fed Rate Decision

December S&P 500 E-Mini futures (ESZ24) are up +0.22%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.26% this morning as investors looked ahead to the Federal Reserve’s final policy decision of the year.

Barchart

Stocks Decline Ahead of Wednesday’s FOMC Meeting Results

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.61%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.43%. Dec E-mini S&P futures (ESZ24 ) are down -0.48%, and Dec E-mini Nasdaq futures...

Barchart

Stocks Fall on Weakness in Chip Makers and Healthcare Companies

The S&P 500 Index ($SPX ) (SPY ) today is down -0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.51%. Dec E-mini S&P futures (ESZ24 ) are down -0.51%, and Dec E-mini Nasdaq futures...

Barchart

Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook

Pfizer stock jumped Tuesday after the pharma giant issued a mixed outlook for 2025. Revenue missed forecasts, while earnings beat some.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?

AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock.

The Guardian - UK

More ‘discreet’ Viagra-type drug could soon be available in Britain

US company Viatris has applied for a UK trademark for wafer-like film that dissolves in the mouth

Creative Bloq

"I’d love to see fewer boundaries in the design industry”: a day in the life of Amy Globus

Team's co-founder discusses approaching design with an artist's sensibility.

Top News

President-Elect Trump Hosts Pharmaceutical Ceos For Dinner At Mar-A-Lago

President-elect Trump's dinner with pharmaceutical executives and healthcare appointees highlights industry collaboration and healthcare challenges.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Despite Pfizer's underperformance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Benzinga

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.

MarketBeat

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

Investors Business Daily

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

MarketBeat

Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

International Business Times

Pfizer Not Eligible To Recover $75 Million From Settlement With SEC

Judge ruled that Pfizer could not recover $75 million left over from insider trading SEC settlement.

The Conversation

The latest COVID booster will soon be available. Should I get one? Am I eligible?

Australia’s Therapeutic Goods Administration (TGA) has recently approved a new COVID booster. The shot was developed by Pfizer and targets the JN.1 sub-variant of Omicron.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.